Journal
BIOMEDICINE & PHARMACOTHERAPY
Volume 144, Issue -, Pages -Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.biopha.2021.112247
Keywords
SARS-CoV-2; Coronavirus; miRNAs; Anti-miRNA therapy; miRNA therapy
Funding
- Vetenskapsradet (The Swedish Research Council) [2017-04663]
- Carl Tryggers Stiftelse [CTS:18:279]
- Vinnova [2017-04663] Funding Source: Vinnova
- Swedish Research Council [2017-04663] Funding Source: Swedish Research Council
Ask authors/readers for more resources
COVID-19 is a pneumonia-like disease caused by a coronavirus, and changes in miRNAs are associated with disease severity, targeting these small noncoding-RNAs could potentially alleviate complications.
COVID-19 is a pneumonia-like disease with highly transmittable and pathogenic properties caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which infects both animals and humans. Although many efforts are currently underway to test possible therapies, there is no specific FDA approved drug against SARS-CoV-2 yet. miRNA-directed gene regulation controls the majority of biological processes. In addition, the development and progression of several human diseases are associated with dysregulation of miRNAs. In this regard, it has been shown that changes in miRNAs are linked to severity of COVID-19 especially in patients with respiratory diseases, diabetes, heart failure or kidney problems. Therefore, targeting these small noncoding-RNAs could potentially alleviate complications from COVID-19. Here, we will review the roles and importance of host and RNA virus encoded miRNAs in COVID-19 pathogenicity and immune response. Then, we focus on potential miRNA therapeutics in the patients who are at increased risk for severe disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available